CG Pharmaceuticals Presents Promising Results for Ivaltinostat in Metastatic Pancreatic Cancer at ASCO GI Symposium

CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity i...

January 24, 2025 | Friday | News
AstraZeneca Announces C$820 Million Investment in Ontario, Creating Over 700 High-Skilled Jobs

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines,  announced a C$820 million (US$570m) investment in Canada,...

January 24, 2025 | Friday | News
Akeso’s Cadonilimab Combination Therapy Shows Landmark Survival Benefits in Advanced Gastric Cancer, Published in Nature Medicine

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of ...

January 23, 2025 | Thursday | News
Labviva CEO Siamak Baharloo on Transforming Life Sciences Procurement with Innovation and AI

In a conversation with BioPharma BoardRoom, Siamak Baharloo, the visionary Co-founder and CEO of Labviva, delves into the transformative role of technology...

January 22, 2025 | Wednesday | Interview
Beckman Coulter Life Sciences and Indiana University Secure $2.5M Grant to Boost Leukemia and Lymphoma Testing in Kenya

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, along with the Indiana University School of Medicine, have been a...

January 22, 2025 | Wednesday | News
Grifols Receives $21 Million Grant from The Michael J. Fox Foundation to Advance Early Detection of Parkinson's Disease

Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, announced it has received a...

January 15, 2025 | Wednesday | News
Libtayo® Demonstrates Significant Improvement in Disease-Free Survival for High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 C-POST Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment wi...

January 14, 2025 | Tuesday | News
AbbVie and Simcere Zaiming Partner to Develop SIM0500 for Relapsed/Refractory Multiple Myeloma

NORTH CHICAGO, Ill. and SHANGHAI, AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) ann...

January 14, 2025 | Tuesday | News
Bioxytran Publishes Groundbreaking Research on Galectin-3 Modulation to Enhance Cancer Immunotherapy Efficacy

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...

January 14, 2025 | Tuesday | News
HMNC Brain Health Reaches Key Milestone with Successful Patient Randomization in Phase 2b OLIVE Trial for Major Depressive Disorder

HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive co...

January 14, 2025 | Tuesday | News
Windward Bio Launches with $200M Series A Financing to Develop Breakthrough Immunology Treatments

Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...

January 12, 2025 | Sunday | News
QIAcuity Digital PCR Expands Capacity to 12 Targets Simultaneously with New Software Update and High Multiplex PCR Kit

  QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold inc...

January 13, 2025 | Monday | News
Agios Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for PYRUKYND® in Thalassemia Treatment

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

January 09, 2025 | Thursday | News
Eyebright Medical’s Loong Crystal PR Intraocular Lens Receives NMPA Class III Medical Device Certification

Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collective...

January 08, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close